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INTRODUCTION
The prostate-specific antigen (PSA) era has seen decreases in 
risk and stage migration in prostate cancer (PCa).1 Even so, 
bone metastases still constitute approximately 3% of newly 
diagnosed patients, and 12% of patients without initial evi-
dence are destined to develop bone metastasis during a me-
dian follow-up of 2.2 years.2,3 In advanced stage PCa, bone 
metastasis occurs in more than 80% of cases, with a corre-
sponding high level of morbidity and a 5-year survival rate of 
25%.4 In contrast, the natural history of visceral metastasis is 
poorly characterized. Although metastasis to the viscera was 
previously considered uncommon and clinically irrelevant, 
autopsy studies of men who died of PCa demonstrate visceral 
involvement in up to 66% of cases.5 Thus, the prognostic im-
pact of visceral disease on survival deserves consideration.
Androgen deprivation therapy (ADT) is the first-line therapy 
for patients with metastatic PCa (mPCa); nevertheless, castra-
tion resistance is destined to emerge, conferring an increased 
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risk of cancer-specific mortality (CSM).6 The heterogeneous 
natural history of mPCa progression to castration-resistant 
PCa (CRPC) and eventual CSM poses a challenge to treating 
clinician. The ability to identify risk factors of progression to 
CRPC and CSM in treatment-naïve patients with mPCa would 
represent an important advance in identifying the underlying 
mechanisms of CRPC development and disease progression. 
Such knowledge would facilitate early identification of those 
most likely to benefit from targeted therapy to prevent or de-
lay progression. Intensive monitoring could optimize the like-
lihood of a successful intervention, and those at low risk of 
progression could avoid unnecessary testing.
A few population-based observational studies have reported 
on survival outcomes in patients with mPCa,7,8 and a number 
of predictive models have been developed based on variables 
pertaining to survival.9,10 However, to the best of our knowledge, 
data are limited regarding survival outcomes according to site 
of metastasis in treatment-naïve patients initially diagnosed 
with mPCa. In such patients, previous intervention would not 
confound survival analysis.
The aims of this study were to 1) explore the distribution of 
metastatic sites in treatment-naïve patients initially diagnosed 
with mPCa, 2) evaluate predictors pertaining to progression 
to CRPC and CSM, and 3) investigate how the site of metasta-
sis and clinicopathological features may adversely affect sur-
vival outcomes.
MATERIALS AND METHODS
Patient selection 
A retrospective analysis was performed from a prospectively 
collected database of 440 consecutive treatment-naïve patients 
diagnosed with mPCa between August 2000 and June 2012. Pa-
tients were stratified into four groups: men with bone metas-
tasis only without pain; the same but with pain; men with vis-
ceral metastasis only; and men with both bone and visceral 
metastases. The presence of enlarged regional pelvic lymph 
nodes was excluded from the definition of metastasis. PCa stag-
ing was determined according to the 7th American Joint Com-
mittee on Cancer (AJCC) TNM system, with the definition of 
distant metastasis based on either demonstrable metastatic 
deposits on imaging (bone scan, computerized tomography, 
magnetic resonance imaging, or positron emission tomogra-
phy) or pathologic confirmation of PCa from tissue outside 
the prostatic fossa. Patients were excluded from analysis if 
they met the following criteria: 1) incomplete clinical data; 2) 
lost to follow-up; 3) previous treatment targeted at PCa, includ-
ing bone-sparing agents; and 4) unknown cause of death. Pa-
tients had regular serum PSA measurements and imaging fol-
low-up at least six months apart. All patients received ADT 
consisting of luteinizing hormone-releasing hormone ago-
nists with or without anti-androgens, with docetaxel being the 
routinely administered first-line cytotoxic chemotherapy fol-
lowing progression to CRPC. The initiation and regimens of 
ADT and cytotoxic chemotherapy were based on physician 
discretion and patient preference. This study was approved by 
the institutional ethics committee after review of the protocol 
and procedures employed (3-2014-0112).
Prognostic factors and outcome variables
Covariates consisted of patient age, body mass index (BMI), 
hemoglobin, alkaline phosphatase, Gleason score, PSA and 
PSA nadir levels, AJCC stage, Visual Analogue Scale (VAS) pain 
score, Eastern Cooperative Oncology Group performance score 
(ECOG PS), Charlson Comorbidity Index (CCI), CRPC status, 
time to CRPC progression, and the site of metastasis. Pain was 
defined as a VAS pain score ≥1, which included conditions re-
quiring anesthetics, palliative radiation therapy, or surgery. 
Pathologic outcomes were based on previous reports confirm-
ed by a single genitourinary pathologist at our institution. CRPC 
was defined as progression of disease or elevation of serum 
PSA using the Prostate Cancer Working Group 2 (PCWG2) cri-
teria,11 with progression to CRPC-free interval defined as the 
time from the date of the first diagnosis of mPCa to the date of 
CRPC diagnosis. The CSM interval was defined as the interval 
from the first diagnosis of mPCa to the date of death from PCa. 
For all patients, the status of survival and cause of death were 
investigated through the National Cancer Registry Database 
or by institutional electronic medical records.
Study endpoints
The primary endpoint was to identify prognostic factors asso-
ciated with progression to CRPC and CSM. The secondary end-
point was to investigate how metastatic site and the clinico-
pathological feature of pain affected survival outcome.
Statistical analysis
Demographic characteristics of patients and tumors were com-
pared using descriptive statistics. Appropriate comparative 
tests, such as the Student’s t-test and χ2-test, were used to com-
pare continuous and categorical variables. Kaplan-Meier 
curves were used to estimate survival of men with bone me-
tastasis stratified by the presence of pain compared to men 
with visceral metastasis. Univariate and multivariate analyses 
were performed according to Cox-proportional hazards regres-
sion models in order to adjust for potential confounders in pre-
dicting survival. Variables considered potential predictors for 
multivariate modeling were selected by univariate analysis. 
Statistical analysis was performed using SPSS version 18 (SPSS 
Inc., Chicago, IL, USA). All tests were two-sided, with statistical 
significance set at p<0.05.
http://dx.doi.org/10.3349/ymj.2015.56.5.12061208
Impact of Metastatic Site in Prostate Cancer
RESULTS
Patient characteristics
Among 440 initially diagnosed treatment-naïve patients with 
mPCa, 248 (56.4%), 158 (35.9%), and 34 (7.7%) patients were di-
agnosed with bone metastasis only, visceral metastasis only, 
and both bone and visceral metastases, respectively. Clinico-
pathologic features of each group are presented in Table 1. Pa-
tients with bone metastasis were more likely to be diagnosed 
at a higher stage and grade of PCa, and to have higher PSA 
and PSA nadir levels, VAS pain score (≥1), and ECOG PS (≥1), 
compared to men with visceral metastasis. The groups were 
comparable in terms of age, BMI, and distribution of CCI (≥4). 
Metastases were most often to bone (75.4%), followed by lung 
(16.3%) and liver (8.3%).
Predictors of progression to CRPC and cancer-specific 
death
Multivariate analyses revealed bone metastasis [hazard ratio 
(HR)=2.790; 95% confidence interval (CI) 1.616–4.819], pres-
ence of pain (HR=1.883; 95% CI 1.120–3.168), and high BMI ( 
HR=1.119; 95% CI 1.046–1.196) to be associated with an in-
creased risk of progression to CRPC. However, tumor grade and 
stage, initial PSA level, and time to PSA nadir following ADT did 
not predict emergence of CRPC (Table 2). Bone metastasis 
(HR=1.758; 95% CI 1.152–2.683), presence of pain (HR=1.861; 
95% CI 1.177–2.910), ECOG PS ≥1 (HR=1.006; 95% CI 1.002–
1.011), and PSA nadir (HR=1.002; 95% CI 1.001–1.002) were sig-
nificant predictors of CSM. Of note, initial PSA level at diagno-
sis and progression to CRPC were not associated with CSM 
(Table 3).
Progression to CRPC-free survival and cancer-specific 
survival outcomes
Survival results as of March 2014 were used in this analysis. 
With pain revealed as a predictor for survival in the multivari-
able analysis, patients with bone metastasis were stratified ac-
cording to the presence of pain and compared to patients with 
visceral metastasis and those with both bone and visceral me-
tastases. The median intervals from initial diagnosis of metas-
tasis to CRPC progression and CSM, as well as the survival out-
come of each group, are presented in Table 4 and Fig. 1. Due to 
clinicopathological heterogeneity across subgroups, which 
may have confounded our ability to determine the influence 
of bone metastasis and the presence of pain on survival out-
comes, we evaluated the comparative survival of patients after 
adjustment for covariates considered potential predictors by 
the Cox-proportional hazards analysis. For all study endpoints, 
patients with bone metastasis accompanied by pain and pa-
tients with both bone and visceral metastases had the worst 
median survivals, followed by men with bone metastasis with-
out pain. Patients with visceral metastasis had the best medi-
an survivals.
Table 1. Clinicopathological Features of 440 Patients with Metastatic Prostate Cancer According to Site of Metastasis
Bone metastasis only Visceral metastasis only Bone and visceral metastases
Number 248 158 34
Age (yrs) 71.5 (66–77) 72.1 (68–77) 72 (67–78)
Body mass index (kg/m2) 23.3 (21.1–25.1) 23.5 (21.4–25.8) 23.9 (21.8–26.3)
ECOG PS (≥1) 65 (26.2%) 32 (14.8%) 9 (26.5%)
CCI (≥4) 186 (75.0%) 122 (77.2%) 28 (82.3%)
VAS pain score (≥1) 96 (38.7%) 51 (23.7%) 14 (41.2%)
Laboratory values
PSA (ng/mL) 100.1 (33.4–389) 60.6 (40.5–119) 142.5 (81.9–448)
PSA nadir (ng/mL) 1.21 (0.08–9.57) 0.75 (0.03–5.8) 1.41 (0.08–13.7)
Hemoglobin (gm/dL) 12.1 (11.6–13.3) 12.9 (11.7–14.2) 12.5 (10.9–13.3)
ALP (IU/L) 118.5 (75.2–294) 79.0 (62.0–109) 104.0 (89.5–147)
Gleason score (%)
≤7 48 (19.4) 49 (31.0) 3 (8.9)
8 90 (36.3) 54 (34.2) 18 (52.9)
≥9 110 (44.3) 55 (34.8) 13 (38.2)
T stage (%)
≤T2 18 (7.3) 29 (18.4) 2 (5.9)
T3 137 (55.2) 76 (48.1) 14 (41.2)
T4 93 (37.5) 53 (33.5) 18 (52.9)
Cytotoxic chemotherapy 121 (48.8) 31 (19.6) 17 (50.0)
ALP, alkaline phosphatase; CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance score; PSA, prostate-specific antigen; 
VAS, Visual Analogue Scale.
Data are number (%) and median (IQR).
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DISCUSSION
In this retrospective analysis of treatment-naïve patients ini-
tially diagnosed with mPCa, the site of metastasis and the 
presence of pain were independent predictors of both pro-
gression to CRPC and CSM. Patients with bone metastasis 
showed worse progression to CRPC-free and cancer-specific 
survival rates than men with visceral metastasis. Among pa-
tients with bone metastasis, men without pain demonstrated 
better survival outcomes than men with pain, who exhibited 
comparable outcomes with men with both bone and visceral 
metastases. 
The tumor microenvironment is a rich source of variable 
soluble factors that play a critical role in tumor aggressiveness 
and androgen sensitivity, a key feature of PCa cells.12 Bone is 
the single most dominant site of metastasis and is a metastatic 
Table 2. Predictors of Progression to Castration-Resistant Disease in Patients with Metastatic Prostate Cancer
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age 0.975 (0.957–0.994) 0.011 0.983 (0.952–1.016) 0.320
Body mass index 1.058 (1.002–1.117) 0.042 1.119 (1.046–1.196) 0.001
ECOG PS (≥1) 1.895 (1.342–2.677) <0.001 1.235 (0.636–2.399) 0.534
CCI (≥4) 0.887 (0.785–1.001) 0.053
VAS pain score (≥1) 2.141 (1.579–2.904) <0.001 1.883 (1.120–3.168) 0.017
PSA 1.076 (0.727–1.593) 0.714
PSA nadir 1.005 (1.001–1.009) 0.005 1.002 (0.995–1.010) 0.544
Time to PSA nadir 1.099 (0.564–2.141) 0.782
Hemoglobin 0.907 (0.054–13.29) 0.907
ALP 1.002 (1.000–1.004) 0.054
PSA response* 0.962 (0.862–1.075) 0.496
Gleason score (≥8) 2.654 (1.831–3.847) <0.001 1.430 (0.796–2.568) 0.232
T stage (≥T3) 3.848 (2.332–6.351) <0.001 1.497 (0.777–2.884) 0.228
Metastatic site
Viscera 1 (Reference) 1 (Reference)
Bone 3.643 (2.631–5.045) <0.001 2.790 (1.616–4.819) <0.001
ALP, alkaline phosphatase; CCI, Charlson Comorbidity Index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance score; HR, haz-
ard ratio; PSA, prostate-specific antigen; VAS, Visual Analogue Scale.
*Time to PSA nadir following androgen deprivation therapy.
Table 3. Predictors of Cancer-Specific Death in Patients with Metastatic Prostate Cancer
Univariate Multivariate
HR (95% CI) p value HR (95% CI) p value
Age 1.007 (0.981–1.023) 0.547
Body mass index 1.017 (0.948–1.091) 0.642
ECOG PS (≥1) 2.501 (1.609–3.891) <0.001 1.006 (1.002–1.011) 0.008
CCI (≥4) 1.045 (0.896–1.212) 0.575
VAS pain score (≥1) 2.501 (1.803–3.939) <0.001 1.861 (1.177–2.910) 0.002
PSA 1.365 (0.853–2.185) 0.194
PSA nadir 1.002 (1.001–1.002) <0.001 1.002 (1.001–1.002) 0.001
Hemoglobin 1.161 (0.567–2.376) 0.719
ALP 1.001 (1.000–1.002) 0.073
Gleason score (≥8) 2.121 (1.318–3.409) 0.002 1.935 (0.918–4.079) 0.083
T stage (≥T3) 1.409 (0.754–2.948) 0.251
Progression to CRPC 1.512 (0.786–3.106) 0.261
Time to CRPC progression 1.084 (0.981–1.201) 0.132
Metastatic site
Viscera 1 (Reference) 1 (Reference)
Bone 2.286 (1.537–3.399) <0.001 1.758 (1.152–2.683) 0.009
ALP, alkaline phosphatase; CCI, Charlson Comorbidity Index; CRPC, castration-resistant prostate cancer; ECOG PS, Eastern Cooperative Oncology Group perfor-
mance score; PSA, prostate-specific antigen; VAS, Visual Analogue Scale; HR, hazard ratio; CI, confidence interval.
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site in 90% of patients with mPCa.13 The propensity of PCa to 
preferentially metastasize to bone may be explained by the 
fact that the bone microenvironment provides a fertile setting 
for the growth and aggressive development of PCa cells.14,15 
Metastasis to the bone may contribute to the emergence of 
CRPC and disease progression, and several studies have re-
ported a number of factors in the bone microenvironment that 
may facilitate castration resistance, namely, epidermal growth 
factor, insulin-like growth factor (IGF), keratinocyte growth 
factor (FGF-7), and interleukin (IL)-6.16-18 Moreover, factors 
secreted from the local bone environment as a result of osteo-
clastic bone resorption, namely IGF-I, transforming growth 
factor-β, bone morphogenic proteins, parathyroid hormone-
related protein, IL-1, and IL-6, have been shown to aid PCa 
cells in escaping apoptosis, developing treatment-resistant 
phenotypes, and continuing to proliferate and grow.19-21 An in 
vitro experimental study found that co-culture of PCa cells 
with bone stromal cell lines induces PCa cells to become an-
drogen resistant.22 Our results are consistent with a popula-
tion-based study of metastatic CRPC patients in which surviv-
al of men with visceral metastasis was affected by the degree 
of bone involvement.23 These observations imply that the mo-
lecular basis for the development of androgen resistance is 
linked to fundamental changes in the bone microenviron-
ment, which may provide an explanation for the increased 
overall survival seen in patients treated by bone-targeted ra-
diopharmaceuticals that exert a potent effect on both PCa 
cells and host cells within the bone.15,24
We observed that bone metastasis is associated with an in-
creased risk of progression to CRPC and CSM and that this as-
sociation is stronger for bone metastasis complicated with 
pain. Pain, pathological fracture, spinal cord compression, and 
Table 4. Survival Outcomes of 440 Patients with Metastatic Prostate Cancer, Stratified According to Site of Metastasis and Presence of Pain
Bone metastasis only Visceral metastasis 
only
Bone and visceral 
metastasesWithout pain With pain
No. (%) 152 96 158 34
No. progression to CRPC (%) 72 (47.4) 69 (71.9) 47 (29.7) 23 (67.6)
Time, progression to CRPC (months) 20.3 (7.7–32.9) 14.3 (9.1–19.5) 34.2 (11.9–56.5) 20.4 (10.5–42.8)
No. cancer-specific deaths (%) 30 (19.7) 45 (46.9) 17 (10.8) 16 (47.1)
Time, cancer-specific death (months) 37.1 (17.9–56.3) 24.5 (12.6–36.4) 42.8 (22.5–63.2) 30.8 (16.7–51.5)
Survival (%)
CRPC progression-free
2-yr 65.1 34.3 87.1 50.9
3-yr 52.6 28.3 83.7 43.8
Cancer-specific
2-yr 88.1 75.6 93.1 77.0
3-yr 78.2 57.8 89.1 64.6
Follow-up period (months) 41.0 (28.1–53.9) 27.3 (16.7–38.9) 45.0 (23.9–66.1) 38.7 (21.8–56.1)
CRPC, castration-resistant prostate cancer; IQR, interquartile range.
Data are number (%) and median (IQR).
Fig. 1. Comparative survival curves of patients with metastatic prostate cancer for (A) progression to castration-resistant prostate cancer (CRPC)-free 
survival and (B) cancer-specific survival.
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bone surgery all represent a spectrum of skeletal-related 
events that have been shown to predict poor prognosis.2 Our 
results are consistent with observations of the US Surveillance, 
Epidemiology, and End Results (SEER)-Medicare and Danish 
National Patient Registry-based studies, which reported similar 
results in patients with bone mPCa.2,25 Although the underly-
ing mechanism is unclear, an increased mechanical and 
chemical stimulation of periosteal or endosteal pain receptors 
resulting from increased overall disease burden may be perti-
nent.26 Unfortunately, we failed to detect any association be-
tween the degree of pain and the extent of bone metastasis in 
our cohort. Gandaglia, et al.27 recently reported outcomes of 
patients from the SEER database in which men with visceral 
metastasis showed inferior overall survival to that of men with 
bone metastasis. Of note, the inferior outcome was not signifi-
cant for CSM. While the underlying mechanism of disparate 
survival outcome according to metastatic site observed be-
tween studies is unclear, we emphasize that retrospective 
studies should be cautiously interpreted within their limita-
tions. Nonetheless, based on our results, we suggest pain as a 
valuable surrogate marker for survival in patients with bone 
mPCa, and that in turn, may be of direct relevance for early 
identification of poor survival. Palliation of symptoms may 
provide opportunities for a favorable clinical outcome.
PSA nadir level following ADT has been used as a useful 
prognosticator of disease progression and survival in various 
disease settings.28 Our results are in accordance to previous 
studies that have observed significant associations between 
PSA nadir and progression to CRPC.29 Moreover, we observed 
that obesity is associated with an increased risk of progression 
to CRPC. It has been widely reported that obese patients have 
higher risks of PCa-related death and disease progression.30 
Although the underlying mechanism thereof is not fully under-
stood, obesity-associated leptin and adiponectin have been 
suggested to adversely affect disease progression by promot-
ing angiogenesis and PCa cell growth, respectively.31
Our study serves to inform clinical practice by highlighting 
that the prognosis of patients diagnosed of mPCa depends on 
multiple patient factors. The identification of clinical surro-
gates that capture early progression to CRPC and survival 
would be significant for several reasons. The natural history of 
men with initially diagnosed mPCa is heterogeneous and dif-
ficult to estimate using exclusively “classic” prognostic factors, 
namely, PSA kinetics, stage, and grade of the disease. Our re-
sults may refine prognosis and allow risk stratification of pa-
tients with mPCa at an early stage of diagnosis. Also, further 
evidence regarding the inter-relationship between PCa cells 
and bone microenvironment shifts the paradigm for under-
standing PCa growth and development of CRPC in bone, which 
may lead to development of therapies that target not only PCa 
cells but also supporting cells of the microenvironment.14
The strengths of the current study include the incorporation 
of detailed clinicopathologic data, information on treatment, 
comorbidities other than cancer, and performance status in-
formation that was available for each patient. Moreover, a sin-
gle institutional cohort may justify the uniformity of the data. 
At the same time, we acknowledge several limitations: first, 
our study is limited by its observational, retrospective design, 
and results should be interpreted accordingly. Due to the het-
erogeneity of this population, there was a lack of standard 
therapeutic approach, and a physician and patient preference 
existed regarding the implementation of a specific treatment. 
Second, a subset of patients had evidence of bone metastasis 
based on technetium-99m bone scans, which are limited by 
inaccuracies and uncertainties arising from lack of specificity 
and inter-observer variability.32 Third, the prognostic factors 
that we identified were determined at the time of metastasis, 
and not before. Thus, the results may not be generalizable to 
evaluating risk for the average patient at the time of PCa diag-
nosis or after a certain definitive treatment.
 This observational study uncovered novel findings on the 
patterns of metastatic spread and presence of pain, which may 
impact prognosis differently in patients initially diagnosed with 
mPCa. Bone seems to provide a crucial environment in the de-
velopment of CRPC and CSM, implying that bone-targeted 
therapies for men at high risk for bone metastasis may poten-
tially delay progression to CRPC and reduce risk of CSM. Fur-
ther elucidation of the complex molecular interactions be-
tween PCa cells and the bone microenvironment may open 
new avenues for treatment.
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